| answer text |
<p>The UK National Screening Committee (UK NSC) advises Ministers and the National
Health Service in all four countries about all aspects of screening policy and supports
implementation.</p><p> </p><p> </p><p> </p><p>The UK NSC is currently reviewing newborn
screening for very long chain acyl CoA dehydrogenase deficiency (VLCADD) against its
internationally recognised criteria. A public consultation on the screening review
opened on 21 November 2014 and will close on 23 February 2015. A copy of the consultation
is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.screening.nhs.uk/fattyacidoxidation"
target="_blank">http://www.screening.nhs.uk/fattyacidoxidation</a></p><p> </p><p>
</p><p> </p><p>Improving education and awareness of rare diseases across the healthcare
professions, including VLCADD, is a commitment in the UK Strategy for Rare Diseases.
The Department continues to work closely with its delivery partners to implement the
Strategy.</p><p> </p>
|
 |
